Pricing Log in Create free account

AIM ImmunoTech Inc. (AIM) vs Niki BioSolutions, Inc. (NIKI)

AIM ImmunoTech Inc. and Niki BioSolutions, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Niki BioSolutions, Inc. are of similar size ($6.9M and $6.8M). Niki BioSolutions, Inc. grew revenue faster over the last twelve months: 42.6% against −21.5%. Niki BioSolutions, Inc. has the higher net margin (−921.7% vs −15,021.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Niki BioSolutions, Inc. leads on 11 and AIM ImmunoTech Inc. on 4.

Valuation

Metric AIM NIKI Biotechnology median
P/E n/m n/m 8.50
P/S 30.63 n/m 9.71
P/B 0.38 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.69 n/m 0.64
EV/Sales (69.58) 1.25 9.21
Earnings yield (1,718.41%) (330.05%) (33.15%)
Free cash flow yield (502.43%) 0.00% (25.50%)

Profitability

Metric AIM NIKI Biotechnology median
Gross margin (23.16%) (87.96%) 65.16%
Operating margin (11,724.21%) 0.00% 0.00%
Net margin (15,021.05%) (921.74%) 0.00%
Free cash flow margin (15,385.26%) 0.00% 0.00%
Return on equity (2,382.30%) 0.00% (56.36%)
Return on assets (169.28%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AIM NIKI Biotechnology median
Revenue growth (TTM) (21.49%) 42.64% 6.02%
EPS growth (last fiscal year) 72.19% 75.64% 30.26%
Revenue growth, 5-year CAGR (11.60%) 2.38% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM NIKI Biotechnology median
Debt to equity 0.00 0.25 0.00
Current ratio 2.11 0.78 4.72
Net debt to EBITDA 0.22 0.02 0.96

Dividend

Metric AIM NIKI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AIM NIKI Biotechnology median
Market cap 6.79m 6.92m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack